Edgewise Therapeutics, Inc. (EWTX)
USD 30.01
(-0.53%)
USD 30.01
(-0.53%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -91.94 Million | -52.63 Million | -33.5 Million | -14.63 Million | -9.17 Million |
| Net Income | -100.16 Million | -67.64 Million | -42.81 Million | -17.12 Million | -9.7 Million |
| Depreciation & Amortization | 1.73 Million | 538 Thousand | 272 Thousand | 185 Thousand | 123 Thousand |
| Deferred income taxes | - | - | -2.29 Million | -203 Thousand | -48 Thousand |
| Stock-based compensation | 17.56 Million | 10.92 Million | 4.4 Million | 354 Thousand | 77 Thousand |
| Change in working capital | -1.56 Million | 4.08 Million | 4.63 Million | 1.95 Million | 334 Thousand |
| Other non-cash items | -9.51 Million | -543 Thousand | 2.29 Million | 203 Thousand | 48 Thousand |
| Investing Cash Flow | 102.88 Million | -70.57 Million | -242.22 Million | -24.38 Million | -180 Thousand |
| Investments in PPE | -5.74 Million | -5.54 Million | -668 Thousand | -203 Thousand | -180 Thousand |
| Acquisitions | -108.63 Thousand | 65.03 Thousand | 241.55 Thousand | - | - |
| Investment purchases | -255.86 Million | -292.38 Million | -288.2 Million | -24.17 Million | - |
| Sales/Maturities of investments | 364.49 Million | 227.35 Million | 46.64 Million | - | - |
| Other Investing Activities | 108.63 Thousand | -65.03 Thousand | -241.55 Thousand | -24.17 Thousand | - |
| Financing Cash Flow | 53.16 Million | 129.63 Million | 186.38 Million | 120.27 Million | 24.8 Million |
| Debt repayment | - | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 53.33 Million | 129.16 Million | 186.14 Million | 120.27 Million | 24.8 Million |
| Other Financing Activities | 53.16 Million | 474 Thousand | 236 Thousand | 120.27 Thousand | 24.8 Thousand |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | -92 Thousand | 47 Thousand | 2.65 Million | 521 Thousand | 275 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | -1.46 Million | 4.03 Million | 1.97 Million | 1.42 Million | 59 Thousand |
| Cash at beginning of period | 21.99 Million | 15.56 Million | 104.91 Million | 23.65 Million | 8.2 Million |
| Cash at end of period | 86.09 Million | 21.99 Million | 15.56 Million | 104.91 Million | 23.65 Million |
| Capital Expenditure | -5.74 Million | -5.54 Million | -668 Thousand | -203 Thousand | -180 Thousand |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 64.1 Million | 6.42 Million | -89.35 Million | 81.26 Million | 15.44 Million |
| Free Cash Flow | -97.69 Million | -58.18 Million | -34.17 Million | -14.83 Million | -9.35 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -31.49 Million | -28.52 Million | -100.16 Million | -30.14 Million | -25.71 Million | -21.46 Million |
| Depreciation & Amortization | 534 Thousand | 525 Thousand | 1.73 Million | 533 Thousand | 497 Thousand | 461 Thousand |
| Deferred income taxes | - | - | - | -3.3 Million | 2.18 Million | 1.11 Million |
| Stock-based compensation | 5.22 Million | 4.87 Million | 17.56 Million | 5.15 Million | 4.55 Million | 4.01 Million |
| Change in working capital | 3.19 Million | -2.31 Million | -1.56 Million | -201 Thousand | 974 Thousand | -342 Thousand |
| Other non-cash items | 846 Thousand | 1.99 Million | -9.51 Million | -2.17 Million | -4.55 Million | -4.01 Million |
| Investing Cash Flow | 37.36 Million | -268.3 Million | 102.88 Million | 26.98 Million | 23.41 Million | 3.44 Million |
| Investments in PPE | -221 Thousand | -297 Thousand | -5.74 Million | -161 Thousand | -457 Thousand | -759 Thousand |
| Acquisitions | - | - | -108.63 Thousand | -27.14 Thousand | -23.87 Thousand | -4201.00 |
| Investment purchases | -40.95 Million | -327.6 Million | -255.86 Million | -39.78 Million | -84.66 Million | -114.45 Million |
| Sales/Maturities of investments | 78.54 Million | 59.59 Million | 364.49 Million | 66.93 Million | 108.54 Million | 118.65 Million |
| Other Investing Activities | 37.58 Million | -268.01 Million | 108.63 Thousand | 27.14 Thousand | 23.87 Thousand | 4201.00 |
| Financing Cash Flow | 1.95 Million | 241.07 Million | 53.16 Million | 52.98 Million | -211 Thousand | 369 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2 Million | 241.07 Million | 53.33 Million | 53.15 Million | -211 Thousand | 369 Thousand |
| Other Financing Activities | 1.95 Million | 1.92 Million | 53.16 Million | 52.98 Million | -211 Thousand | 369 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.89 Million | 780 Thousand | -92 Thousand | -1.38 Million | 1.76 Million | -312 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.3 Million | -3.09 Million | -1.46 Million | 1.18 Million | -788 Thousand | -30 Thousand |
| Cash at beginning of period | 30.26 Million | 86.09 Million | 21.99 Million | 32.95 Million | 31.8 Million | 48.23 Million |
| Cash at end of period | 43.48 Million | 30.26 Million | 86.09 Million | 86.09 Million | 32.95 Million | 31.8 Million |
| Capital Expenditure | -221 Thousand | -297 Thousand | -5.74 Million | -161 Thousand | -457 Thousand | -759 Thousand |
| Effect of forex changes on cash | - | - | - | -23.84 Million | 3.4 Million | 20.43 Million |
| Net cash flow / Change in cash | 13.22 Million | -55.83 Million | 64.1 Million | 53.14 Million | 1.15 Million | -16.42 Million |
| Free Cash Flow | -26.32 Million | -28.89 Million | -97.69 Million | -26.99 Million | -22.51 Million | -20.99 Million |
GTLL
ARHS
UMIYA
CTKB
KHADIM
SULA